Table 2. Odds ratio for overt thyroid irAE development.
OR/Adjusted OR (95% CI) | p | |
---|---|---|
Univariate analysis | ||
Sex (Female > Male) | 2.60 (0.86–7.85) | 0.090 |
Thyroid uptake of FDG-PET | 19.91 (4.79–82.79) | < 0.001 |
TSH > 2.5 μIU/mL | 3.06 (0.91–10.28) | 0.071 |
Multivariate analysis | ||
Sex (Female > Male) | 1.62 (0.41–6.37) | 0.493 |
Thyroid uptake of FDG-PET | 14.48 (3.12–67.19) | < 0.001 |
TSH > 2.5 μIU/mL | 2.68 (0.67–10.67) | 0.162 |
Statistical analysis was performed using logistic regression model.
Results of thyroid uptake of FDG-PET and TSH were obtained before nivolumab therapy.
OR: odds ratio, CI: confidence interval